hydroxyurea

Treatment strategies included supportive care, interferon, hydroxyurea, and ruxolitinib. PMF and SMF demonstrate distinct clinical phenotypes despite sharing bone marrow fibrosis as a common endpoint. The mutational landscape highlights the genetic heterogeneity of MF and underscores the importance of integrating clinical, pathological, and molecular information to improve disease characterization and guide individualized management.

P2/3, N=207, Active, not recruiting, Sobi Inc. | Recruiting --> Active, not recruiting

P2, N=107, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Completed

Secondary prevention included dual antiplatelet therapy, therapeutic phlebotomy, and cytoreductive therapy with hydroxyurea...Long-term outcomes depend on integration of standard acute coronary syndrome therapy with disease-specific cytoreductive strategies to reduce recurrent thrombosis. This case reinforces that acute coronary syndromes should not be routinely attributed to atherosclerotic disease when clinical and angiographic features are disproportionate to traditional risk profiles.

P2, N=45, Not yet recruiting, St. Jude Children's Research Hospital

Modern treatment approaches, including therapeutic phlebotomy, low-dose aspirin, and cytoreductive therapies (hydroxyurea, interferon-α formulations, and ruxolitinib), have reduced blood cell counts and thrombotic risk, yet concerns about treatment-associated cardiovascular toxicity have emerged. Recent cardio-oncology guidelines emphasize structured monitoring for cancer therapy-related cardiovascular toxicity. This mini review summarizes the cardiovascular burden of PV, therapeutic strategies to mitigate risk, and emerging perspectives on cardiotoxicity-including a recently reported case of reversible left ventricular dysfunction associated with ropeginterferon α-2b.

P3, N=136, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd

Preclinical experiments confirmed IL-1β upregulation with fibrosis progression, reversed by ruxolitinib or pegylated interferon-α but not hydroxyurea (hydroxycarbamide). This multicentre pilot proof-of-concept study demonstrates that an interpretable blood-based tool shows preliminary accuracy for identifying moderate-to-severe MF and underscores IL-1β as a mechanistic biomarker. The data support potential utility as a complementary approach; bone marrow biopsy remains the reference standard.

P1/2, N=1000, Recruiting, Oslo University Hospital HF | N=6000 --> 1000

Prior Hydroxyurea (HU) use was independently associated with secondary malignancy (OR = 2.73; 95% CI 1.33-5.61; p = 0.006), alongside age and leukocytosis...Cytoreductive therapy was associated with reduced thrombotic risk, while HU exposure was linked to secondary malignancies and disease progression, probably reflecting a high disease burden in the latter. This underscores the need for refined risk stratification and long-term surveillance in LR-PV.

P2, N=153, Suspended, RTOG Foundation, Inc. | Recruiting --> Suspended

Phase III data from PROUD-PV (NCT01949805; EudraCT, 2012-005259-18) and its phase IIIb extension, CONTINUATION-PV (NCT02218047; EudraCT, 2014-001357-17), demonstrate that ropeg, compared with hydroxyurea, achieves hematologic response more slowly but provides greater, more durable responses after ∼18 months, underscoring the importance of long-term adherence. Early adverse events can challenge adherence, emphasizing the need for proactive symptom management. This review offers evidence- and experience-based perspectives on long-term ropeg treatment and adverse event management to support adherence and maximize therapeutic benefit in PV.